Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, November 19th.

Anixa Biosciences Price Performance

ANIX opened at $2.58 on Tuesday. The company’s 50 day simple moving average is $2.84 and its two-hundred day simple moving average is $3.02. The firm has a market capitalization of $83.02 million, a price-to-earnings ratio of -6.62 and a beta of 0.90. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. On average, equities analysts anticipate that Anixa Biosciences will post -0.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Amit Kumar purchased 43,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were bought at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the purchase, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 22.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Anixa Biosciences

A number of institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of Anixa Biosciences in the third quarter valued at approximately $34,000. Concorde Asset Management LLC purchased a new stake in Anixa Biosciences during the second quarter worth approximately $31,000. Westside Investment Management Inc. lifted its position in shares of Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after buying an additional 21,100 shares during the last quarter. International Assets Investment Management LLC increased its position in shares of Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares in the last quarter. Finally, Tyler Stone Wealth Management increased its position in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after buying an additional 21,008 shares during the period. 29.13% of the stock is owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.